Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
24 hedge funds and large institutions have $15.8M invested in Astria Therapeutics in 2017 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 6 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
51% more capital invested
Capital invested by funds: $10.4M → $15.8M (+$5.37M)
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
0.25% more ownership
Funds ownership: 32.92% → 33.17% (+0.25%)
0% more funds holding
Funds holding: 24 → 24 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WS
Wedbush Securities
Los Angeles,
California
|
+$336K |
| 2 |
VF
Virtu Financial
New York
|
+$184K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$143K |
| 4 |
Renaissance Technologies
New York
|
+$84.7K |
| 5 |
OC
Oppenheimer & Co
New York
|
+$68.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$441K |
| 2 |
ARTA
A.R.T. Advisors
New York
|
-$88.1K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$21K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$8.42K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$7K |
ATXS Hedge Fund Activity: Q3 2017 in Review
24 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2017, worth a combined $15.8M — up 51% from $10.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ATXS positions and 6 closed out — a net gain of 1 holder — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Wedbush Securities, adding an estimated $336K. The largest seller was Rhenman & Partners Asset Management, exiting entirely with an estimated $441K sold.
- 24 institutional investors held Astria Therapeutics (ATXS) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $15.8M of Astria Therapeutics stock for Q3 2017, up 51% quarter-over-quarter.
- 7 funds opened new Astria Therapeutics positions in Q3 2017 and 6 closed out, a net change of +1 holder.
- The largest Astria Therapeutics buyer in Q3 2017 was Wedbush Securities, an estimated $336K added.
- The largest Astria Therapeutics seller in Q3 2017 was Rhenman & Partners Asset Management, an estimated $441K sold.
Based on aggregated 13F filings for Q3 2017.